Connect your AI

aTyr Pharma ATYR Finance Lease, Right-of-Use Asset, after Accumulated Amortization

Finance Lease, Right-of-Use Asset, after Accumulated Amortization at other companies

L3Harris TechnologiesLHX

$192M-5.0%

ON SemiconductorON

$0-100%

Xcel EnergyXEL

$1.43B—

Duke EnergyDUK

$3M-57.1%

T-Mobile USTMUS

$2.77B-7.1%

State StreetSTT

$182M+34.8%

Other financials

Income statement

Revenue-—

Operating income-$11.4M+27.5%

Net income-$10.8M+27.5%

EPS (diluted)-$0.11+35.3%

Balance sheet

Cash & equivalents$10.0M-3.4%

Total debt$12.3M-9.2%

Total equity$57.9M-22.8%

Total assets$79.7M-18.1%

Cash flow

Operating cash flow-$12.5M+18.8%

CapEx$138.0K—

Free cash flow-$12.7M+17.9%

Valuation

Market cap$54.88M-88.2%

Enterprise value$57.17M—

P/S288.8×—

Profitability

Operating margin-40,856.3%+28,833pp

Net margin-39,009.5%+29,653pp

FCF margin-32,664.7%+4,018pp

Returns & leverage

Return on equity-105.3%+50.6pp

Debt / equity0.2×0.0×

Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAsset.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's finance lease, right-of-use asset, after accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is aTyr Pharma's finance lease, right-of-use asset, after accumulated amortization?: aTyr Pharma (ATYR) reported finance lease, right-of-use asset, after accumulated amortization of $447K in Q1 2026.
How has aTyr Pharma's finance lease, right-of-use asset, after accumulated amortization changed year-over-year?: aTyr Pharma's finance lease, right-of-use asset, after accumulated amortization decreased by 57.1% year-over-year, from $1.04M to $447K.